Trials / Withdrawn
WithdrawnNCT02976441
Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Feasibility of Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that this study will show that sufficient lymphocyte stem cell can be harvested prior chemoradiation and be reinfused back after treatment, and at least 5 of the 10 patients (50%) will achieve an absolute increase of lymphocyte counts of 300 cells/mm\^3 four weeks after stem cell reinfusion in high grade glioma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiation therapy | |
| DRUG | Temozolomide | |
| PROCEDURE | Stem cell collection | |
| PROCEDURE | Stem cell infusion |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2016-11-29
- Last updated
- 2017-02-20
Source: ClinicalTrials.gov record NCT02976441. Inclusion in this directory is not an endorsement.